2023. Genetic Polymorphism in CYP2D6 and its Association with the Safety and Efficacy of Fluvoxamine in Patients with Major Depressive Disorder . Precision Medicine Communications. 3, 1 (Jun. 2023), 43–49. DOI:https://doi.org/10.55627/pmc.003.01.0301.